Page last updated: 2024-11-04
ropinirole and Anasarca
ropinirole has been researched along with Anasarca in 1 studies
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Ropinirole XL/PR was titrated/continued, and adjusted as appropriate during the maintenance phase (maximum 24 mg/d)." | 2.82 | Long-term, open-label, safety study of once-daily ropinirole extended/prolonged release in early and advanced Parkinson's disease. ( Asgharian, A; Ellis, J; Jimenez, T; Makumi, CW; Shaikh, S; VanMeter, S, 2016) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Makumi, CW | 1 |
| Asgharian, A | 1 |
| Ellis, J | 1 |
| Shaikh, S | 1 |
| Jimenez, T | 1 |
| VanMeter, S | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| An Open-Label Extension Study With REQUIP (Ropinirole) CR for Subjects From Studies 101468/165, 101468/168 and 101468/169[NCT00632736] | Phase 3 | 419 participants (Actual) | Interventional | 2004-02-29 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Number of Participants With the Indicated Number of Adverse Events (AEs) and Serious Adverse Events (SAEs)
AEs, defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, were collected to obtain data on the safety, tolerability, and benefit of ropinirole XL. SAEs, defined as AEs that are fatal, life threatening, disabling/incapacitating, resulting in hospitalization or prolongation of a hospital stay, a congenital abnormality/birth defect, or any important medical occurrence that the investigator regards as serious based on medical judgment, were also collected. st. med., study medication. (NCT00632736)
Timeframe: 13 February 2004 through 31 March 2010
| Intervention | participants (Number) |
|---|
| Participants (Par.) reporting at least one AE | Par. reporting at least one SAE | Par. with drug-related AEs | Par. with AEs leading to withdrawal |
|---|
| Ropinirole XL | 365 | 109 | 213 | 106 |
Number of Participants With the Indicated Response to the Patient Preference Question at Week 4 and Week 26
"The patient preference question assessed the participant's preference for either dosing regimen of study drug, once a day versus three times a day. Participants were asked to respond to the following question to assess preference: Please indicate whether you preferred taking your Parkinson's tablets 3 times a day or once a day. Wk, Week." (NCT00632736)
Timeframe: Week 4 and Week 26
| Intervention | participants (Number) |
|---|
| Very much preferred three times a day, Wk 4, n=74 | Much preferred three times a day, Week 4, n=74 | Preferred three times a day, Week 4, n=74 | Both regimens are about the same, Week 4, n=74 | Preferred once a day, Week 4, n=74 | Much preferred once a day, Week 4, n=74 | Very much preferred once a day, Week 4, n=74 | Very much preferred three times a day, Wk 26, n=87 | Much preferred three times a day, Week 26, n=87 | Preferred three times a day, Week 26, n=87 | Both regimens are about the same, Week 26, n=87 | Preferred once a day, Week 26, n=87 | Much preferred once a day, Week 26, n=87 | Very much preferred once a day, Week 26, n=87 |
|---|
| Ropinirole XL | 2 | 0 | 4 | 5 | 17 | 18 | 28 | 4 | 1 | 2 | 4 | 14 | 20 | 42 |
Trials
1 trial available for ropinirole and Anasarca